# Neural Effects of Intravenous N,N-dimethyltryptamine (DMT)

> **NCT07693257** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Jon Dean** · enrollment: 20 (estimated)

## Conditions studied

- Healthy Participants Study

## Interventions

- **DRUG:** N,N-Dimethyltryptamine (15 mg)
- **DRUG:** N,N-Dimethyltryptamine (17.5 mg)

## Key facts

- **NCT ID:** NCT07693257
- **Lead sponsor:** Jon Dean
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2028-09-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07693257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07693257, "Neural Effects of Intravenous N,N-dimethyltryptamine (DMT)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07693257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*